Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Astrocytoma 8Glioblastoma 5Neuroectodermal Tumors, Primitive 3Recurrence 2Oligodendroglioma 2Neurocytoma 2Lymphoma, Non-Hodgkin 2Glioma 2Brain Neoplasms 2Rhabdoid Tumor 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Ganglioglioma 1Esophageal Neoplasms 1Ependymoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Melanoma × antineoplaston AS 2-1 × Clear all
NCT00003509 2020-12-19

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Burzynski Research Institute

Phase 2 Terminated
13 enrolled 5 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡